Dr Danijela Kocic, Scientific Head of Clinical Pharmacology and Toxicology for SydPath, St. Vincent’s Hospital, and Mr James See, APAC Business Lead at Roche Diagnostics Asia Pacific, engage in an insightful dialogue highlighting the pivotal role of mass spectrometry in therapeutic drug monitoring (TDM). Their discussion navigates the complexities of change management during its implementation and the importance of lab-clinician communications in the process. With enhanced mass spectrometry capabilities, SydPath is now able to seamlessly multiplex assays, streamline workflows and expand its analytical scope to encompass steroid profiling, urine drug screening, and proteomics, all in the name of providing better services to patients.